• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Klinck John L. Jr. bought $48,860 worth of shares (14,000 units at $3.49), increasing direct ownership by 26% to 67,593 units (SEC Form 4)

    8/12/24 5:39:19 PM ET
    $CDLX
    Computer Software: Programming Data Processing
    Technology
    Get the next $CDLX alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Klinck John L. Jr.

    (Last) (First) (Middle)
    675 PONCE DE LEON AVENUE NE
    SUITE 4100

    (Street)
    ATLANTA GA 30308

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Cardlytics, Inc. [ CDLX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    08/12/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 08/12/2024 P 14,000 A $3.49 67,593 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    /s/ Nick Lynton, Attorney-in-Fact 08/12/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CDLX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDLX

    DatePrice TargetRatingAnalyst
    10/11/2024$4.00In-line
    Evercore ISI
    8/16/2024$5.00Outperform → Market Perform
    Northland Capital
    8/15/2024$4.00 → $3.50Neutral → Underperform
    BofA Securities
    8/8/2024Buy → Hold
    Craig Hallum
    8/8/2024Buy → Hold
    Needham
    8/8/2024$18.00 → $5.00Buy → Hold
    Lake Street
    6/20/2024$11.00Neutral
    BofA Securities
    6/18/2024$14.00Outperform
    Northland Capital
    More analyst ratings

    $CDLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hill Scott A bought $143,200 worth of shares (40,000 units at $3.58) (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      8/12/24 5:46:37 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Director Hornsey Liane bought $35,900 worth of shares (10,000 units at $3.59) (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      8/12/24 5:45:56 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Director Klinck John L. Jr. bought $48,860 worth of shares (14,000 units at $3.49), increasing direct ownership by 26% to 67,593 units (SEC Form 4)

      4 - Cardlytics, Inc. (0001666071) (Issuer)

      8/12/24 5:39:19 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    SEC Filings

    See more
    • SEC Form S-8 filed by Cardlytics Inc.

      S-8 - Cardlytics, Inc. (0001666071) (Filer)

      5/20/25 4:19:44 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Cardlytics, Inc. (0001666071) (Filer)

      5/20/25 4:04:21 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 10-Q filed by Cardlytics Inc.

      10-Q - Cardlytics, Inc. (0001666071) (Filer)

      5/7/25 4:30:52 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Financials

    Live finance-specific insights

    See more
    • Cardlytics Announces First Quarter 2025 Financial Results

      Cardlytics, Inc. (NASDAQ:CDLX), a digital advertising platform, today announced financial results for the first quarter ended March 31, 2025. "We've made marked progress across our key business pillars, which continue to underpin our journey to 'platformize' Cardlytics and position ourselves as the leading commerce media platform," said Amit Gupta, CEO of Cardlytics. "Our expanding ecosystem, depth and breadth of our data, and ongoing tech investments are strengthening our position and providing differentiated value to our partners and advertisers." "We've built a resilient platform and are making strategic decisions as we look to future-proof our business," said Alexis DeSieno, CFO of Ca

      5/7/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics Announces Timing of Its First Quarter 2025 Earnings Release

      Cardlytics, Inc. (NASDAQ:CDLX) today announced that its financial results for the first quarter ending March 31, 2025 will be released on May 7, 2025, after market close. Conference Call Details: When: May 7, 2025 at 5:00 pm Eastern time / 2:00 pm Pacific time Webcast: Attendees may access the live audio webcast on the Cardlytics Investor Relations website at ir.cardlytics.com, or by registering at this link. Following the call, a replay will be available on the website. Dial-in: Call participants may dial +1 800-549-8228 and use Conference ID: 86123. About Cardlytics Cardlytics (NASDAQ:CDLX) is a commerce media platform, powered by our publishers' first-party purchase data, that

      4/23/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics Announces Fourth Quarter and Full Year 2024 Financial Results

      Cardlytics, Inc. (NASDAQ:CDLX) today announced financial results for the fourth quarter and full year ended December 31, 2024. "While 2024 was a challenging year for Cardlytics, we nevertheless planted the seeds and refocused our efforts to get back on track for growth this year," said Amit Gupta, CEO of Cardlytics. "We remain grounded in our vision for long-term and sustainable growth. We are focused on strengthening our competitive moat through our efforts to modernize our platform, enhance our product and tech capabilities, and expand our network of partners and advertisers." "In 2025, we are focused on delivering sequential improvements and positive Adjusted EBITDA," said Alexis DeSie

      3/12/25 4:05:00 PM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology

    $CDLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evercore ISI initiated coverage on Cardlytics with a new price target

      Evercore ISI initiated coverage of Cardlytics with a rating of In-line and set a new price target of $4.00

      10/11/24 8:36:58 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics downgraded by Northland Capital with a new price target

      Northland Capital downgraded Cardlytics from Outperform to Market Perform and set a new price target of $5.00

      8/16/24 8:54:02 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology
    • Cardlytics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Cardlytics from Neutral to Underperform and set a new price target of $3.50 from $4.00 previously

      8/15/24 7:18:52 AM ET
      $CDLX
      Computer Software: Programming Data Processing
      Technology